Kimberly-Clark Corp. agreed to buy Kenvue Inc. for roughly $40 billion, snapping up the embattled Tylenol maker’s storied brands in a gamble that would vault the Kleenex producer into consumer health’s top tier.Kimberly-Clark agreed to pay a total consideration of $21.01 per Kenvue share, a 46 per cent premium to the Tylenol maker’s closing price on Friday. The deal values Kenvue at $48.7 billion on an enterprise basis, the companies said.The transaction exposes Kimberly-Clark to legal and political peril. ...

Kimberly-Clark has agreed to buy Tylenol maker Kenvue for about $48.7 billion, sending the drug manufacturer’s shares soaring 18% in premarket trading Monday. The deal will create a new consumer health giant, bringing Kenvue under the wing of the maker of Kleenex tissues and Huggies diapers. Kenvue CEO Kirk Perry said it would allow the company to “innovate even faster.” Kenvue has been under pressure in recent weeks amid attacks by the Trump administration on Tylenol, its most recognizable product. Pres ...